VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | ANDROMEDA: daratumumab + CyBorD for AL amyloidosis

Efstathios Kastritis, MD, of the University of Athens School of Medicine, Athens, Greece, discusses the Phase III ANDROMEDA study (NCT03201965) investigating subcutaneous daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients with newly diagnosed amyloid light chain (AL) amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter